KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed FCF Margin for 15 consecutive years, with 9.19% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 1619.0% to 9.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.4% through Dec 2025, down 1947.0% year-over-year, with the annual reading at 6.4% for FY2025, 1947.0% down from the prior year.
  • FCF Margin for Q4 2025 was 9.19% at Supernus Pharmaceuticals, up from 32.17% in the prior quarter.
  • The five-year high for FCF Margin was 41.98% in Q2 2022, with the low at 32.17% in Q3 2025.
  • Average FCF Margin over 5 years is 18.05%, with a median of 24.3% recorded in 2023.
  • The sharpest move saw FCF Margin skyrocketed 3517bps in 2024, then plummeted -6252bps in 2025.
  • Over 5 years, FCF Margin stood at 30.66% in 2021, then tumbled by -46bps to 16.57% in 2022, then surged by 65bps to 27.38% in 2023, then dropped by -7bps to 25.38% in 2024, then tumbled by -64bps to 9.19% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 9.19%, 32.17%, and 35.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.